Sequence of Deposition of Heterogeneous Amyloid Beta-peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation
Overview
Affiliations
Patients with trisomy 21 [Down syndrome (DS)] progressively develop amyloid beta-protein (A beta) deposits and then other features of Alzheimer's disease (AD), apparently due to increased gene dosage and thus expression of the beta-amyloid precursor protein. Because the neuropathological phenotype in older DS subjects closely resembles that of AD, the examination of DS brains of increasing age provides a unique model of the progression of AD. Here, we characterized the deposition of several A beta peptides and apolipoprotein E in formalin-fixed brain sections from 29 DS subjects between 3 and 73 years old. Amyloid plaque number and the percentage of cortical area they occupied were quantified by computerized image analysis. A beta ending at amino acid 42 (A beta 42) was the earliest form of A beta deposited in DS cortex. It was observed in 7 of 16 young (3-30 years) subjects, with the earliest deposition occurring at age 12. A beta ending at residue 40 (A beta 40) was not detected until approximately age 30, a time when degenerating neurites around A beta immunoreactive (IR) plaques were first observed, and the frequency of A beta 40 IR plaques then rose with age. Even in old (51-73 years) DS subjects, A beta 42 IR plaques were always more abundant than A beta 40 IR plaques. A beta peptides starting at aspartate 1 or pyroglutamate 3 were detected in small subsets of compacted, neuritic plaques beginning around age 30 and rose with age, the latter species always exceeding the former. Thus, the N-termini of the A beta 42 peptides abundantly deposited in very young DS subjects remain unknown. Apo E was detectable in a small subset of A beta 42 IR plaques beginning at age 12 and rose steadily with age; it clearly followed the deposition of A beta. Our analysis of very young DS brains suggests that amyloid plaque formation begins with A beta 42-ending peptides, and the number and percentage of cortical area of A beta 42 plaques increase very little with advancing age, while other heterogeneous A beta species and Apo E progressively accrue onto plaques containing A beta 42.
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.
Thal D, Poesen K, Vandenberghe R, De Meyer S Mol Neurodegener. 2025; 20(1):33.
PMID: 40087672 DOI: 10.1186/s13024-025-00819-y.
Polyamine biosynthesis dysregulation in Alzheimer's disease and Down syndrome cellular models.
Sola A, Sandberg A, Pham C, Revier A, Hebinck M, Penney A bioRxiv. 2025; .
PMID: 39974945 PMC: 11838436. DOI: 10.1101/2025.01.31.635912.
Jacob C, Tollenaere M, Kachar H, Potier M, De Deyn P, Van Dam D Heliyon. 2025; 11(1):e41445.
PMID: 39850411 PMC: 11755057. DOI: 10.1016/j.heliyon.2024.e41445.
Koenig K, Bhattacharyya P Brain Sci. 2025; 14(12.
PMID: 39766440 PMC: 11674040. DOI: 10.3390/brainsci14121241.
McLachlan M, Bettcher B, McVea A, DiFillipo A, Zammit M, LeMerise L medRxiv. 2024; .
PMID: 39677434 PMC: 11643166. DOI: 10.1101/2024.12.04.24318526.